4/1
07:30 am
cntx
Context Therapeutics to Participate in Upcoming Investor Conferences
Medium
Report
Context Therapeutics to Participate in Upcoming Investor Conferences
3/26
04:02 pm
cntx
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
Medium
Report
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
3/23
08:50 am
cntx
Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth [Yahoo! Finance]
Low
Report
Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth [Yahoo! Finance]
3/21
08:09 am
cntx
Context Therapeutics Inc. (NASDAQ: CNTX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
Medium
Report
Context Therapeutics Inc. (NASDAQ: CNTX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
3/21
08:09 am
cntx
Context Therapeutics Inc. (NASDAQ: CNTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Medium
Report
Context Therapeutics Inc. (NASDAQ: CNTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
3/20
04:22 pm
cntx
Context Therapeutics Reports Full Year 2024 Operating and Financial Results
Low
Report
Context Therapeutics Reports Full Year 2024 Operating and Financial Results
3/6
08:43 am
cntx
Integral Molecular's Out-licensed Bispecific Antibody Enters Clinical Trial for Treating Solid Tumors [Yahoo! Finance]
Medium
Report
Integral Molecular's Out-licensed Bispecific Antibody Enters Clinical Trial for Treating Solid Tumors [Yahoo! Finance]
2/24
07:07 pm
cntx
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
2/24
05:05 pm
cntx
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/19
07:07 pm
cntx
Context Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Context Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
2/19
07:30 am
cntx
Context Therapeutics to Participate in Upcoming Investor Conferences
Low
Report
Context Therapeutics to Participate in Upcoming Investor Conferences
1/15
07:28 am
cntx
Context Therapeutics Inc. (NASDAQ: CNTX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
High
Report
Context Therapeutics Inc. (NASDAQ: CNTX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
1/14
05:12 pm
cntx
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76 [Yahoo! Finance]
High
Report
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76 [Yahoo! Finance]
1/14
04:58 pm
cntx
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
Low
Report
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
1/13
07:46 am
cntx
Context Therapeutics names Andy Pasternak as chair [Seeking Alpha]
Neutral
Report
Context Therapeutics names Andy Pasternak as chair [Seeking Alpha]
1/13
07:30 am
cntx
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
Low
Report
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
1/9
06:58 am
cntx
Context Therapeutics Inc. (NASDAQ: CNTX) was upgraded by analysts at Citizens Jmp to a "strong-buy" rating.
Medium
Report
Context Therapeutics Inc. (NASDAQ: CNTX) was upgraded by analysts at Citizens Jmp to a "strong-buy" rating.
1/8
07:54 am
cntx
Context Therapeutics Inc. (NASDAQ: CNTX) is now covered by analysts at JMP Securities. They set an "outperform" rating and a $4.00 price target on the stock.
Medium
Report
Context Therapeutics Inc. (NASDAQ: CNTX) is now covered by analysts at JMP Securities. They set an "outperform" rating and a $4.00 price target on the stock.